Structure-based design and synthesis of pyrrole derivatives as MEK inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 14, 2010, Pages 4156-4158

  Wallace, Michael B ^a   Adams, Mark E ^a   Kanouni, Toufike ^a   Mol, Clifford D ^a   Dougan, Douglas R ^a   Feher, Victoria A ^a   O'Connell, Shawn M ^a   Shi, Lihong ^a   Halkowycz, Petro ^a   Dong, Qing ^a  

^a Takeda San Diego Inc   (United States)

Author keywords

MEK; Oncology; Pyrrole

Indexed keywords

PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; CYCLIZATION; DRUG DESIGN; ENZYME ACTIVITY; IN VITRO STUDY; NONHUMAN; RAT; SYNTHESIS;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; MAP KINASE KINASE KINASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PYRROLES; RATS;

EID: 77953872377     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.05.058     Document Type: Article

References (20)

1. Davis R.J. J. Biol. Chem. 268 (1993) 14553
2. Anderson N.G., Maller J.L., Tonks N.K., and Sturgill T.W. Nature 343 (1990) 651
3. Mandell J.W. Am. J. Pathol. 153 (1998) 1411
4. Towatari M., Iida H., Tanimoto M., Iwata H., Hamaguchi M., and Saito H. Leukemia 11 (1997) 479
5. Sivaraman V.S., Wang H., Nuovo G.J., and Malbon C.C. J. Clin. Invest. 99 (1997) 1478
6. Wang D., Boerner S.A., Winkler J.D., and LoRusso P.M. Biochem. Biophys. Acta 1773 (2007) 1248
7. Montagut C., and Settleman J. Cancer Lett. 283 (2009) 125
8. Barrett S.D., Bridges A.J., Dudley D.T., Saltiel A.R., Fergus J.H., Flamme C.M., Delaney A.M., Kaufman M., LePage S., Leopold W.R., Przybranowski S.A., Sebolt-Leopold J., Van Becelaere K., Doherty A.M., Kennedy R.M., Marston D., Howard W.A., Smith Y., Warmus J.S., and Tecle H. Bioorg. Med. Chem. Lett. 18 (2008) 6501
9. Wallace E.M., Lyssikatos J.P., Yeh T., Winkler J.D., and Koch K. Curr. Top. Med. Chem. 5 (2005) 215
10. Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P., Yan C., McConnell P., Spessard C., Banotai C., Mueller W.T., Delaney A., Omer C., Sebolt-Leopold J., Dudley D.T., Leung I.K., Flamme C., Warmus J., Kaufman M., Barrett S., Tecle H., and Hasemann C.A. Nat. Struct. Mol. Biol. 12 (2004) 1192
11. Bauer V.J., and Safir S.R. J. Med. Chem. 15 (1972) 440
12. Madhav R., Dufresne F.F., and Southwick P.L. J. Hetero. Chem. 10 (1973) 225
13. m ATP concentration indicated compounds were not ATP competitive inhibitors.
14. 50s generated for all compounds listed were at a minimum 50-fold higher in the PC3 cell line.
15. Full experimental procedures for compounds 13-26 are contained within the following patent application: Adams, M. E.; Dong, Q.; Kaldor, S. W.; Kanouni, T.; Wallace, M. B. PCT Int. Patent Appl. WO 08/055236, 2008.
16. Danswan G., Kennewell P.D., and Tully W.R. J. Heterocycl. Chem. 26 (1989) 293
17. Matulenko M.A., Lee C.-H., Jiang M., Frey R.R., Cowart M.D., Bayburt E.K., DiDomenico S., Gfesser G.A., Gomtsyan A., Zheng G.Z., McKie J.A., Stewart A.O., Yu H., Kohlhaas K.L., Alexander K.M., McGaraughty S., Wismer C.T., Mikusa J., Marsh K.C., Snyder R.D., Diehl M.S., Kowaluk E.A., Jarvis M.F., and Bhagwat S.S. Bioorg. Med. Chem. 13 (2005) 3705
18. Kinase Panel: Abl1, AKT3, c-RAF, CamK1Δ, CDK2/cyclinA, cMet, cSRC, EGFR, GSK3β, IR, JAK3, P38α, PDGFRβ, PDK1, PKCα, PLK3, Syk, Tie2.
19. Compounds were administered intravenously and orally at 1 and 5 mg/kg, respectively.
20. Protein Data Bank code is 3MBL.